100 Years of Progress in Tuberculosis Treatment
The initial key step in the development of modern chemotherapy for tuberculosis was the demonstration in clinical trials, starting in 1946, that the antibiotic streptomycin might be a viable drug for the disease.
The results of early British trials showed a substantial benefit to the streptomycin arm of the trial; however, soon many patients developed antibiotic resistant strains and little ultimate benefit came to those treated. The next big movement forward came with the introduction of a combination of drugs, including streptomycin, to prevent the emergence of drug-resistant Mycobacterium tuberculosis.
By 1955, clinical trials in Great Britain showed that almost all tuberculosis strains had primary resistance to only one drug. Treatment with a 2- to 3-month three-drug phase, followed by 2 drugs, became the world standard. Yet patients had to take the regimen for 12 months.
In 1956, researchers in Madras, India, found that results from those who were treated with tuberculosis drugs at home compared equally well with those treated at a sanitarium.
Furthermore, they discovered that family members who were in contact with the tuberculosis case daily were no more liable to develop the disease than were relatives of those who were treated at a sanitarium.
Then, using a drug called pyrazinamide discovered in 1952, U.S. researchers working with experimental tuberculosis in mice showed that as bacterial metabolism slowed down from the action of other drugs, pyrazinamide worked with more bactericidal effect. Out of the multiplicity of random clinical trials that were carried out over the years, two drug regimens emerged as treatments of choice.
The first was a 6-month regimen in which rifampin (a potent sterilizing agent) was given throughout the time period. Patients began treatment with 2 months of streptomycin, isoniazid, and pyrazinamide, followed by 4 months of isoniazid, and, as stated, rifampin. (Streptomycin has been replaced with ethambutol in many settings.) The second treatment choice was an 8-month regimen of a combination of these drugs, which a recent randomized clinical trial has shown to be "distinctly inferior to the 6-month regimen with rifampin throughout."
The article about the remarkable history of tuberculosis treatment appears in the first issue for April 2005 of the American Thoracic Society's peer-reviewed American Journal of Respiratory and Critical Care Medicine.
American Thoracic Society Journal news tips for April 2005 (first issue)
For the complete text of these articles, please see the American Thoracic Society Online Web Site at http://www.atsjournals.org. For either contact information or to request a complimentary journalist subscription to ATS journals online, or if you would like to add your name to the Society's twice monthly journal news e-mail list, contact Cathy Carlomago at 212-315-6442, or by e-mail at ccarlomagno@thoracic.org .
Contact: Cathy Carlomagno
ccarlomagno@thoracic.org
212-315-6442
American Thoracic Society
http://www.thoracic.org
100 de ani de progrese în tratamentul tuberculozei - 100 Years of Progress in Tuberculosis Treatment - articole medicale engleza - startsanatate